Monday, November 5, 2012
Pa. Gets Cut of $181 Mil. Risperdal Settlement With Janssen
While Pennsylvania has been unsuccessful so far in bringing state court claims that it was defrauded by off-label marketing by Janssen Pharmaceuticals of its antipsychotic drug Risperdal, the state will now share in a $181 million settlement with the company over similar claims.
Subscribe to:
Post Comments (Atom)
Risperdal reproached.
ReplyDeleteSame saga here as Eli Lilly Zyprexa.
Johnson and Johnson is a trusted brand we associate with babies.
Risperdal,Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. An estimated 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder,many of these foster children.
Weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease.
Eli Lilly made $67 BILLION on Zyprexa!
*Tell the truth don't be afraid*
Daniel Haszard
FMI zyprexa-victims(dot)com